PubMed HealthSearch

Biomedical subjects

Hidenori Arai

Publications and source records attributed to Hidenori Arai.

2 recordsLinked to original sources

Multimodal intervention benefits: Responder analysis of J-MINT PRIME Kanagawa trial.

INTRODUCTION: The J-MINT PRIME Kanagawa trial was an 18-month multimodal intervention (incorporating exercise, nutrition, and metabolic management) for dementia prevention. Because the primary analysis showed no significant benefits, we performed an exploratory responder analysis to identify responsive subpopulations. METHODS: We analyzed the Full Analysis Set comprising 188 participants. Classification and regression tree (CART) analysis, applied to the intervention arm, identified baseline predictors of cognitive improvement. These rules were then applied to the entire cohort to evaluate treatment effects on the Mini-Mental State Examination (MMSE) using fully adjusted mixed-effects models for repeated measures (MMRM). RESULTS: CART identified a "Target Group" (N = 108) characterized by baseline profiles such as an MMSE score < 28 or specific metabolic ranges (e.g., LDL-C < 135 mg/dL). Within this target group, the intervention significantly preserved MMSE trajectories compared with the control group (group &#xd7; time interaction, P = 0.022). In contrast, the Non-Target Group (N = 80), consisting of high-functioning individuals (MMSE &#x2265; 28), exhibited no significant group &#xd7; time interaction. DISCUSSION: Multimodal interventions may effectively preserve global cognition in older adults with sub-threshold cognitive decline. Careful targeting of appropriate populations, while considering potential longitudinal measurement artifacts (e.g., practice effects), is essential. These findings provide a hypothesis-generating framework that warrants external validation in future prevention trials.

Humans

Elevated plasma GFAP levels in MCI link APOE &#x3b5;4 allele with impaired gait speed.

The presence of at least one copy of the apolipoprotein &#x3b5;4 allele (APOE &#x3b5;4) is a known predictor of gait impairment risk among older adults. However, the mechanisms by which APOE &#x3b5;4 affects gait performance remain unclear. This cross-sectional study aimed to reveal underlying pathological mechanisms linking APOE &#x3b5;4 carriage to slow gait. This secondary analysis used baseline assessments from the J-MINT multicenter intervention trial, focusing on older adults with mild cognitive impairment. Gait speed was measured at baseline, with slow gait (SG) defined as speeds one standard deviation below the age- and sex-specific mean. APOE phenotype and plasma biomarkers related to Alzheimer's disease (AD), including amyloid-&#x3b2; composite biomarker, phosphorylated Tau 181, neurofilament light, and glial fibrillary acidic protein (GFAP), were also measured. The analysis included 236 non-APOE &#x3b5;4 carriers and 84 carriers of at least one APOE &#x3b5;4. APOE &#x3b5;4 carriers exhibited significantly slower gait speed than non-carriers (1.20 m/s [SD&#x2009;=&#x2009;0.22] vs 1.26 m/s [SD&#x2009;=&#x2009;0.23], p&#x2009;=&#x2009;0.042). Significant interaction between APOE &#x3b5;4 carriage and SG was observed only in plasma GFAP levels (F1, 312&#x2009;=&#x2009;7.17, p&#x2009;=&#x2009;0.008), indicating that individuals with APOE &#x3b5;4 and SG had significantly higher plasma GFAP levels. Elevated plasma GFAP levels fully mediated the association between APOE &#x3b5;4 carriage and gait speed (partially standardized indirect effect&#x2009;=&#x2009;-0.059: -0.12 to -0.013]). No other AD-related biomarkers mediated this association. Our results suggest that APOE &#x3b5;4-related gait changes may reflect AD pathology, as indicated by elevated GFAP levels, and could potentially accelerate dementia symptoms.

Aged